Maveropepimut-s is a subunit vaccine commercialized by IMV, with a leading Phase II program in Fallopian Tube Cancer, Peritoneal Cancer and Epithelial Ovarian Cancer. According to Globaldata, it is involved in 17 clinical trials, of which 5 were completed, 8 are ongoing, 2 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Maveropepimut-s’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Maveropepimut-s is expected to reach an annual total of $51 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Maveropepimut-s (DPX-Survivac) is under development for the treatment of glioblastoma, ovarian cancer, fallopian tube cancer, bladder cancer, liver cancer (hepatocellular carcinoma), non-small cell lung (NSCLC) cancer as well as tumors shown to be positive for the microsatellite instability-high (MSI-H) biomarker, diffuse large B-cell lymphoma, peritoneal cancer and (HR+/HER2-) breast cancer. It is administered subcutaneously. It comprises survivin-based antigens formulated in the DepoVax delivery platform and DPX platform. It was also under development for the treatment of prostate cancer.
IMV, formerly Immunovaccine Inc, is a biopharmaceutical company that develops immunotherapies and vaccines to treat cancer and infectious diseases. The company is investigating its pipeline candidates DPX-Survivac against ovarian, bladder, liver, non-small cell lung cancer and diffuse large B cell lymphoma (DLBCL); DPX-RSV for Respiratory Syncytial Virus (RSV); and DPX-Covid-19 for the treatment of coronavirus. It is also advancing DPX-SurMAGE against bladder cancer and DPX-BRAF to treat melanoma. IMV harnesses its proprietary DPX platform technology to deliver drugs. The company partners with pharmaceutical companies, academic research institutions and government agencies to research and develop therapies for cancer. IMV is headquartered in Dartmouth, Nova Scotia, Canada.
The company reported revenues of (US Dollars) US$0.2 million for the fiscal year ended December 2021 (FY2021), a decrease of 16.4% over FY2020. The operating loss of the company was US$35.7 million in FY2021, compared to an operating loss of US$26 million in FY2020. The net loss of the company was US$36.6 million in FY2021, compared to a net loss of US$26.1 million in FY2020. The company reported revenues of US$0.1 million for the third quarter ended September 2022, compared to a revenue of US$0.1 million the previous quarter.
For a complete picture of Maveropepimut-s’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.